SavedAdd your journal

Journals / BEYOGLU EYE JOURNAL / 2017 / Cilt: 2 - Sayı: 2

Intravitreal Ranibizumab for Diabetic Macular Edema Patients with Good Baseline Visual Acuity: A Real-Life Study

Abdullah ÖZKAYA
Mehmet ÖZVEREN
Zeynep ALKIN
Pages
53–57
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, adherence to the needed treatment regimen seems to be insufficient in real life and probably limits the visual success in this group of patients

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This is a report of 12-month real-life outcomes of ranibizumab treatment in diabetic macular edema (DME) patients who had a baseline visual acuity (VA) ≥0.6 in decimals.Methods: Newly diagnosed treatment-naïve DME patients with a VA ≥0.6 who completed a follow-up of 12 months after treatment with ranibizumab were included retrospectively.
📊
Key Findings & Data:The patients were evaluated in terms of change in best corrected visual acuity (BCVA) and central retinal thickness (CRT), and the total number of visits and injections.Results: A total of 27 eyes of 24 patients were included.
💡
Conclusion & Impact:However, adherence to the needed treatment regimen seems to be insufficient in real life and probably limits the visual success in this group of patients
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: This is a report of 12-month real-life outcomes of ranibizumab treatment in diabetic macular edema (DME) patients who had a baseline visual acuity (VA) ≥0.6 in decimals.Methods: Newly diagnosed treatment-naïve DME patients with a VA ≥0.6 who completed a follow-up of 12 months after treatment with ranibizumab were included retrospectively. The patients were evaluated in terms of change in best corrected visual acuity (BCVA) and central retinal thickness (CRT), and the total number of visits and injections.Results: A total of 27 eyes of 24 patients were included. Mean BCVA at baseline, month 3, 6, 9, and 12 was 0.77±0.11 in decimals, 0.72±0.23, 0.72±0.18, 0.70±0.21, and 0.71±0.19, respectively. Mean CRT at baseline, month 3, 6, 9, and 12 was 420±79, 394±97, 341±54, 360±102, and 350±106 microns, respectively. The mean number of visits and injections was 4.8±1.0 and 3.5±1.5, respectively.Conclusion: Ranibizumab seems to be effective in maintaining VA and improving anatomy in DME patients with a good baseline VA. However, adherence to the needed treatment regimen seems to be insufficient in real life and probably limits the visual success in this group of patients

🔖

Cite This Article

ÖZKAYA, A., ÖZVEREN, M., ALKIN, Z. (2017). Intravitreal Ranibizumab for Diabetic Macular Edema Patients with Good Baseline Visual Acuity: A Real-Life Study. BEYOGLU EYE JOURNAL, Cilt: 2 - Sayı: 2, 53–57. https://ajindex.com/articles/160755

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Jusufbegovic D, Mugavin MO, Schaal S. Evolution of controlling diabetic retinopathy: Changing Trends in the Management of Diabetic Macular Edema at a Single Institution Over the Past Decade. Retina 2015;35:929–34
  2. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report no
  3. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin 1987;27:265–72
  4. Ozkaya A, Alagoz C, Alagoz N, Gunes H, Yilmaz I, Perente I, et al. Dexamethasone implant in pseudophakic and nonglaucomatous subgroup of diabetic macular edema patients: a real life experience. Eur J Ophthalmol 2016;26:351–5
  5. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064–77.e35
  6. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447–9
  7. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615–25
  8. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789–801
  9. Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX-DME Study Group. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes. Ophthalmology 2017;124:74–81
  10. Menchini U, Bandello F, De Angelis V, Ricci F, Bonavia L, Viola F, et al. Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study). J Ophthalmol 2015;2015:324841
  11. Ghanchi F, Hazel CA. South Asian diabetic macular oedema treated with ranibizumab (ADMOR)-real-life experience. Eye (Lond) 2016;30:133–8
  12. Mitchell P, Wong TY; Diabetic Macular Edema Treatment Guideline Working Group. Management paradigms for diabetic macular edema. Am J Ophthalmol 2014;157:505–13
  13. Schatz H, Madeira D, McDonald HR, Johnson RN. Progressive